Aptose Biosciences Inc. Annual report pursuant to Section 13 and 15(d)

Note 15 - Selected Quarterly Financial Data (Unaudited) (Tables)

12 Months Ended

Dec. 31, 2022

Selected financial data (unaudited) for the periods presented was as follows:


	March 31, 2022			June 30, 2022			September 30, 2022			December 31, 2022
Revenue	$	—		$	—		$	—		$	—
Net loss		(11,481	)		(10,565	)		(9,777	)		(10,000	)
Basic and diluted loss per common share		(0.12	)		(0.11	)		(0.11	)		(0.11	)


	March 31, 2021			June 30, 2021			September 30, 2021			December 31, 2021
Revenue	$	—		$	—		$	—		$	—
Net loss		(16,227	)		(13,470	)		(11,333	)		(24,324	)
Basic and diluted loss per common share		(0.18	)		(0.15	)		(0.13	)		(0.27	)